key: cord-0682887-ql7kg82m authors: Pekayvaz, Kami; Leunig, Alexander; Kaiser, Rainer; Brambs, Sophia; Joppich, Markus; Janjic, Aleksandar; Popp, Oliver; Polewka, Vivien; Wange, Lucas E.; Gold, Christoph; Kirchner, Marieluise; Muenchhoff, Maximilian; Hellmuth, Johannes C; Scherer, Clemens; Eser, Tabea; Deák, Flora; Kuhl, Niklas; Linder, Andreas; Saar, Kathrin; Tomas, Lukas; Schulz, Christian; Enard, Wolfgang; Kroidl, Inge; Geldmacher, Christof; von Bergwelt-Baildon, Michael; Keppler, Oliver T.; Zimmer, Ralf; Mertins, Philipp; Hubner, Norbert; Hölscher, Michael; Massberg, Steffen; Stark, Konstantin; Nicolai, Leo title: Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection date: 2021-02-03 journal: bioRxiv DOI: 10.1101/2021.02.03.429351 sha: 342ec231ea7c7f852a46c06393d1533101c71761 doc_id: 682887 cord_uid: ql7kg82m The immune system of most SARS-CoV-2 infected individuals limits viral spread to the upper airways without pulmonary involvement. This prevents the development of pneumonic COVID-19. However, the protective immunological responses causative of successful viral containment in the upper airways remain unclear. Here, we combine longitudinal single-cell RNA sequencing, proteomic profiling, multidimensional flow cytometry, RNA-Seq of FACS-sorted leukocyte subsets and multiplex plasma interferon profiling to uncover temporally resolved protective immune signatures in non-pneumonic and ambulatory SARS-CoV-2 infected patients. We compare host responses in a high-risk patient population infected with SARS-CoV-2 but without pulmonary involvement to patients with COVID-19 pneumonia. Our data reveal a distinct immunological signature of successful viral containment, characterized by an early prominent interferon stimulated gene (ISG) upregulation across immune cell subsets. In addition, reduced cytotoxic potential of Natural Killer (NK) and T cells, as well as a monocyte phenotype with immune-modulatory potential are hallmarks of protective immunity. Temporal resolution across disease trajectories highlights ISG upregulation as particularly prominent early in the disease and confirms increased expression also in comparison to healthy controls. We validate this distinct temporal ISG signature by in-depth RNA-seq of FACS-sorted leukocyte subsets in a large prospective ambulatory SARS-CoV-2 infected cohort confirming early and robust ISG upregulation particularly in monocytes and T cells. In conclusion, our data demonstrate a protective ISG phenotype in patients with successful containment of SARS-CoV-2 infection without progression to COVID-19. This early protective interferon response might be exploited as a therapeutic approach and for disease course prediction. Due to its high contagiousness and an approximate case fatality rate of 1.0-2.3% the COVID-19 pandemic has confronted the world with a major health care and economic challenge [1] [2] [3] . Approximately 10% of cases have a severe disease course 4 . Extensive data now underlines immunopathology, the concept of self-inflicted damage to tissues by the immune system, as an important factor contributing to disease progression in COVID-19 [4] [5] [6] [7] [8] . Various detrimental pathways have been identified to drive immunopathology in COVID-19: A cytokine storm with high levels of IL-6 with some similarity to CAR-T cell hyperinflammation was postulated 9, 10 . Recent data highlighted a failure in host interferon I and III responses associated with progression to severe COVID-19 [11] [12] [13] . In contrast to influenza, severe COVID-19 has also been associated with impaired Interferon- expression levels in T cells 4, 7, 14 . Seminal work revealed auto-antibodies against interferon pathway related proteins and inherent dysfunctional mutations in a significant proportion of severe COVID-19 cases 15, 16 . T cells in severe cases show upregulation of exhaustion and apoptosis markers 5 . Apart from adaptive immunity, the concept of a dysregulated innate immune cell axis evolved consistently across studies, with an expansion of HLA-DR low monocytes and a surge in (premature) neutrophils, which in turn cause vascular inflammation and immunothrombosis in the lung and remote organs 17-20 . Interestingly, most infected patients, even those with known risk factors like hypertension or obesity, efficiently clear SARS-CoV-2 without developing pneumonia 21, 22 . This highlights the ability of the host immune system to mount an effective response and contain the virus in the upper airways without causing pulmonary damage in the majority of cases 23 . Yet, the pathways that provide protective immunity in SARS-CoV-2 infection are less well understood. Outpatients and patients with oligo-and asymptomatic SARS-CoV-2 infection, who represent the exemplary immune response, have been underrepresented in mechanistic studies. To better understand how protective immune response and immunopathology differ in SARS-CoV-2 infection, we launched a two-cohort multi-omics study characterizing the immune response in ambulatory and non-pneumonic infected individuals. With this experimental approach, we first used a well characterized, exploratory cohort of high-risk patients for hypothesis generation and subsequently confirmed our findings in a large cohort of outpatient SARS-CoV-2 infected individuals. A multi-omics approach allowed us to identify protective cell responses in these individuals by contrasting them with COVID-19 pneumonia cases and healthy controls in a longitudinal manner. We identify a distinct immunological signature of successful viral containment, featuring a prominent, early interferon stimulated gene (ISG) upregulation across immune cell subsets which is independent of plasma interferon levels. In addition, reduced cytotoxic potential of Natural Killer (NK) and T cells, as well as a monocyte phenotype with immune-modulatory properties were hallmarks of protective immunity. Longitudinal clinical and cellular characteristics of the successful and failing immune response to SARS-CoV-2 We compared high risk patients with an immune response that successfully prevents pulmonary involvement in SARS-CoV-2 infection to the response of patients developing COVID-19 pneumonia. We performed single cell RNA sequencing (sc-RNA seq), in-depth RNA sequencing of sorted immune cell populations, 50-dimensional flow cytometry, plasma shotgun proteomics together with cytokine profiling longitudinally throughout the disease course. We used a longitudinally sampled exploratory high-risk cohort for hypothesis generation (n=14 patients) and a longitudinally sampled outpatient confirmation cohort to validate our results (n=58 patients) (see Methods). For the exploratory cohort, the three sampling time points were after first positive PCR test (TP1), on average five days after initial sampling (TP2) and after negative PCR/seroconversion or symptomatic improvement (TP3) (Figure 1a -b Suppl Fig 1a-b and Methods). In our exploratory cohort, radiological assessment of non-pneumonic, SARS-CoV-2 infected patients revealed no signs of lung injury on high-resolution computed tomography compared to patients experiencing pulmonary symptoms (Figure 1c ). Upper respiratory tract viral loads derived from nasopharyngeal swabs between pneumonic and non-pneumonic patients in the exploratory group were comparable (Figure 1d ). Patients in the exploratory cohort had on average 2.9 risk factors for developing a severe disease course, with all patients having at least 1 risk factor for a severe disease course, and a trend towards more risk factors in the non-pneumonic cohort (Suppl. Table 1 , see methods). Absolute leukocyte counts did not differ between groups, while other inflammatory markers such as CRP, IL-6 and Lactate Dehydrogenase (LDH) were elevated in the pneumonic group as expected (Figure 1e ). Further differentiation of leukocyte subsets revealed lower lymphocyte counts in the pneumonic group, but similar neutrophil and monocyte counts as reported previously (Suppl. Fig. 1c ) 8, 12, 24, 25 . To allow for an in-depth analysis of leukocyte subsets, we performed phenotyping of surface marker expression by flow cytometry (Suppl. Fig. 1d ). We found relative NK-cell counts in non-pneumonic infected patients dropped significantly in comparison to pneumonic patients at timepoint 3 ( Figure 1f ). Similarly, changes in the mononuclear phagocyte (MNP) compartment included no major differences in monocyte subsets and significantly higher relative pDC counts in non-pneumonic patients compared to patients with pulmonary injury ( Figure 1f ). We further observed distinct shifts in T cell populations, mainly presenting with a faster recovery of relative CD4 + T cell counts in non-pneumonic patients, but without numerical changes in CD8 + T cells (Figure 1f ). Unsupervised UMAP-clustering of single cell RNA-seq data of PBMCs identified 17 distinct immune cell populations (Suppl. Fig. 1e ). The subclusters were integrated into the following immune cell populations: T cells, B cells, monocytes, NK cells, myeloid dendritic cells, plasmacytoid dendritic cells, plasma cells and gamma delta T cells (Figure 1g Taken together, comparison of non-pneumonic and pneumonic patients revealed only mild global changes in circulating immune cells and plasma proteins, consistent with previous reports 18 . To better understand how the cellular response to SARS-CoV-2 infection might shape disease course, we next analyzed our transcriptomic data in detail. 33, 34 . We therefore asked if the observed differences simply indicated a down-regulation of the interferon response in severe COVID-19. However, when comparing non-pneumonic SARS-CoV-2 infected patients with uninfected control patients, we found persistent differential expression, pointing towards an active enhancement of ISG signaling in peripheral immune cells as a key immunological feature in non-pneumonic disease (Suppl. Fig.3b , d-f). To further validate these findings, we computed an ISG-score for each cell population 12 . Indeed, the summarized ISG score across all cell populations revealed that non-pneumonic cases displayed a substantial rise compared to pneumonic patients but also compared to non-COVID-19 controls (Figure 2j ). The strong increase in ISGs between pneumonic and non-pneumonic COVID-19 patients was reproducible across CD4 + T cells, NK cells and was particularly prominent in monocytes ( Figure 2k ). Finally, gene ontology (GO) term analysis of biological processes revealed an enrichment of "defense response to virus", "response to virus", "response to interferon-alpha" "response to type I interferon", "negative regulation of NK cell activation markers and neutrophil chemoattractants S100A9 and S100A8 40 were less abundantly expressed in non-pneumonic infected patients. In line, NK cells from pneumonic patients showed an upregulation of GO terms such as "cytolysis", "granulocyte chemotaxis" and "granulocyte migration" (Figure 3c , Suppl. Fig. 4b ). Flow cytometry-based surface profiling revealed five NK cell subpopulations among pneumonic and non-pneumonic patient groups characterized by differential surface expression (Suppl. Fig. 4c-g) . Subpopulation NK2, characterized by increased expression levels of CD18 necessary for cytotoxic activity 41 , and CD9, a tetraspanin implicated in innate immune cell activation and diapedesis 42 , was detected at high levels throughout pneumonic disease (Suppl. Fig. 4d , f). Similarly, infected patients without lung injury showed a less cytotoxic CD8 + T cell transcriptomic phenotype with decreased expression levels of cytotoxic genes such as In summary, elevated levels of cytotoxicity in lymphocytes seem to be dispensible for an effective upper-airway containment in non-pneumonic SARS-CoV-2 infection. In-depth analysis of CD4 + T cells revealed higher counts of antigen inexperienced CD45RA + CD4 + T cells in non-pneumonic patients, most pronounced at late stages ( Figure 4a ). In line, antigen experienced CD45RO + CD4 + T cells diverged significantly during the disease course in non-pneumonic compared to pneumonic patients (Suppl. Fig. 5a ). tSNE analysis with subsequent FlowSOM subclustering of T cell panel 1 revealed a distinct CD4 + CD45RA + CCR10 int subpopulation (TC6) to be significantly enriched in non-pneumonic patients, with an increased divergence over the disease course (Suppl. Fig. 5b-f ). TC6 was further characterized by particularly low expression of surface activation and exhaustion markers, including CXCR3, PD-1 and CTLA-4 52 (Suppl. Fig. 5c ). Interestingly, CXCR3, which is rapidly induced upon activation of naïve T cells, was expressed only at low levels in In line, and similar to CD8 + T cells, CD4 + T-cells from non-pneumonic SARS-CoV-2 infected patients showed downregulation of "cell killing", "chronic inflammatory response" and "cytolysis" GO terms (Figure 4b -d). Corresponding to the expression profiles of T cells, the antiviral transcription factors JUNB, FOS and FOSBpreviously shown to govern IFN production in NK cells 61 Moreover, anti-inflammatory genes like TMEM176B, known to inhibit the inflammasome and therefore IL1-beta production, as well as Interleukin 1 receptor antagonist (IL1RN), showed enhanced transcription in monocytes of non-pneumonic infection (Figure 4h) 66 . Finally, epidermal growth factor receptor (EGFR) ligands, which control tissue repair and regeneration, as well as mucosal immunity, were found to be significantly enhanced in nonpneumonic cases (Figure 4h ) 67 . In particular, Ampheregulin (AREG), Epiregulin (EREG), Early growth response protein 3 (EGR3), and Heparin Binding EGF Like Growth Factor (HBEGF) showed significant upregulation (Figure 4h ). AREG has been shown to modulate T reg and Th2 function 68, 69 , while EREG is crucial for epithelial integrity and resolution of inflammation 70 . Longitudinal analysis revealed that the identified pathways were most prominently upregulated at TP2, pointing at a pro-resolving and immune-modulatory monocyte phenotype developing later over the disease course (Fig. 4i ). In contrast, in patients developing COVID-19 pneumonia TNFRSF1B and IL6R, genes encoding IL-6 receptor and TNF receptor, were upregulated in pneumonic COVID-19. In addition, effector proteins like lysosomal cysteine protease Cathepsin B were significantly enhanced ( Figure 4j ). Monocytes have also been implicated in contributing to immunothrombosis in COVID-19 71 . Indeed, in addition to complement factors upregulated in the plasma (Figure 1i ), complement factor D and platelet binding PSGL-1 were upregulated in monocytes of pneumonic patients (Figure 4j ). Plasma proteomics showed increased proinflammatory CCL18, as well as Cathepsin G (Figure 4k) 72 . In summary, these data highlight an overall pro-inflammatory and potentially tissue-damaging phenotype of peripheral blood monocytes in COVID-19 pneumonia. Robust early upregulation of ISG signatures in a large ambulatory SARS-CoV2 infected cohort Using a cohort of high-risk patients, we detected a distinct immune profile in non-pneumonic SARS-CoV-2 infection, which was most prominently characterized by a global ISG response across different peripheral immune cell subsets, a lymphocyte shift from cytotoxic to immune-regulatory, and an anti-inflammatory monocyte signature. Longitudinal analysis most notably highlighted an early global ISG response to be decisive for a non-pneumonic disease course, whereas the other identified immune trajectories developed over time. Because of the crucial patho-mechanistic and potentially therapeutic implications, we sought to verify our findings by focusing on ISG expression at an early timepoint upon infection. To again concentrate on protective immunity, we chose a prospective cohort of ambulatory patients, which prospectively enrolled SARS-CoV 2 PCR-positive individuals, who were not hospitalized due to paucity of symptoms (validation cohort: KoCo19-Immu, see Methods) 73, 74 . We included PBMC samples early after RT-PCR-positivity (day 4) and after convalescence (day 60) (n=39). Two additional cross-sectional cohorts of age-matched SARS-CoV-2 negative patients (n=9) and a second hospitalized cohort with COVID-19 pneumonia (n=7) were also analyzed for reference. We performed subset bulk RNAsequencing of sorted major immune cell subsets to allow for a deep transcriptomic coverage (see Methods). In line with the exploratory cohort, ambulatory SARS-CoV-2 infected patients with oligo-to asymptomatic disease showed an early upregulated ISG signature across major PBMC subsets at day 4 compared to after convalescence at day 60 after infection ( Fig 7a-b) . Finally, we computed an ISG score using the same interferons as for the exploratory cohort (Fig 5d) . The ISG score of early disease ambulatory patients was significantly increased compared to convalescent patients, a very similar finding to the ISG score derived from the exploratory cohort scRNA Seq data (Fig 2k) . A similar immune signature emerged upon comparison of day 4 samples with SARS-CoV-2 negative, age-matched controls (Suppl. Fig. 7c ). To test if our findings are consistent, we further compared ambulatory SARS-CoV-2 infection In summary, a large, prospective, ambulatory cohort of SARS-CoV-2 infected patients validated a strong early interferon response to characterize a disease course without substantial lung involvement. Cytokine profiling reveals differences in type II and III interferon plasma levels Next, we asked whether the observed ISG signature in circulating immune cells of SARS-CoV-2 infected ambulatory patients (validation cohort) was due to elevated systemic interferon levels. We deployed multiplex cytokine profiling to longitudinally map circulating plasma interferons at day 4, 11 and convalesce (day 60) of ambulatory (n=40) compared to hospitalized COVID-19 (n=7) and non-COVID-19 control patients (n=9). Interestingly, in contrast to identified ISG responses, non-hospitalized mild cases at early timepoints of infection (d4) had a significantly lower level of interferon type II and type III (IFN-λ1, IFN-λ2/3 and IFN-γ) compared to hospitalized COVID-19 patients (Figure 5e ). However, there was no clear difference between early mild and hospitalized SARS-CoV-2 infection for interferon type I plasma levels, with no difference in circulating IFN-α2 and only slightly higher IFN-β in hospitalized patients (Figure 5f ). There was no difference between d4 and any other timepoints as well as to healthy controls. In summary, despite overt differences in ISGs, cytokine profiling provided no evidence for differences in circulating IFN levels as an explanation for the observed ISG signature across immune cell subsets in nonpneumonic SARS-CoV-2 infected patients. Indeed, the ISG scores of immune cells of hospitalized and day 4 ambulatory patients and their respective plasma interferon levels did not correlate, with no significant correlations across any cell or interferon type (Suppl Fig 7f) . This might indicate either a local ISG induction in the upper airways, independent of plasmainterferons, or interferon-independent inductions of ISG expression 75 . Plasma-interferon independent changes in cellular ISGs might explain the conflicting data currently existing on interferon responses in SARS-CoV-2 infection 13, 18, 19, 76 . The heterogeneity of responses to SARS-CoV-2 infection, ranging from non-pneumonic courses to acute respiratory distress syndrome (ARDS), might hold promise for immune system modulation as a therapeutic approach. Even the majority of patients with high-risk characteristics are able to control the virus in the upper airways 77 . Here, we specifically analyzed immune responses that enable early viral containment without triggering organ damage by focusing on non-pneumonic compared to pneumonic SARS-CoV-2 infection. We utilized an at-risk cohort analyzed with state-of-the-art multi-omics assays to generate hypotheses, which we then validated in a larger prospective validation cohort of ambulatory infected patients. 48, 63 Most importantly, we dissected the features defining a successful immune response against SARS-CoV-2 in non-pneumonic and ambulatory infected individuals. A global upregulation of ISG responses in non-pneumonic SARS-CoV-2 infection were the most prominent changes observed across major peripheral blood immune cell populations. These ISG signatures were most distinctly upregulated at early disease timepoints, which hints at a causative protective function of these pathways. We confirmed these findings in a prospective ambulatory validation study (validation cohort). Interestingly, these changes in ISG signature were not accompanied by increased plasma interferon levels, and cellular ISGs did not correlate with plasma interferon levels. In addition, we found that nonpneumonic SARS-CoV-2 infection was associated with immunomodulatory T cell function with reduced cytotoxicity and a pro-resolving EGFR signature in monocytes. In combination, these trajectories are likely to limit uncontrolled cytokine release and inflammation without simultaneously interfering with a locally and temporally restricted innate and adaptive (mucosal) immune response 67, 78 . In contrast, pneumonic patients showed a reduced early ISG response, but displayed an upregulation of monocyte IL6R, S100A8/A9, and an increased cytotoxicity of T cells and NK. This shift to a proinflammatory phenotype after a failed ISG response might represent a compensatory response, triggering tissue damage and explain immunopathology and cytokine release associated with poor outcome 79 . Conflicting data exist on IFN signaling in COVID-19 depending on (1) patient collective, (2) sampling time points and (3) disease state 13, 18, 19, 76 . It still remains unclear which role plasma interferons and interferon stimulated intracellular pathways play for an uncomplicated disease course. Our work strongly supports the hypothesis of an early pronounced ISG response as key for limiting viral spread at early timepoints, whereas a delayed/suppressed response leads to viral dissemination and an immunopathogenic global inflammatory response 80 Our data show that therapeutic induction of ISGs in immune cells might be a treatment option in early disease. So far, data on interferon-based therapy in COVID-19 is inconclusive, but a study utilizing inhaled nebulized interferon beta-1 in non-severe COVID-19 showed promising results 86, 87 . Intriguingly, retrospective analysis of a cohort trial with IFN-alpha2 indicated that early interferon treatment might be beneficial regarding clinical outcomes, with harmful effects late in the disease 88 . However, side-effects and the abovementioned autoantibodies as well as signaling mutations in patients susceptible to SARS-CoV-2 might limit the use of interferon-alpha or beta 15, 16, 89 . In summary, our data provide important implications for therapy and disease course prediction in SARS-CoV-2 infection. By measuring ISG responses in peripheral immune cells, patients could potentially be segregated in ARDS high/low risk cohorts. Treatment with interferons early in disease might be able to tip the inflammatory response towards local pathogen control, possibly preventing severe COVID-19 and its potentially fatal consequences. The authors thank the patients and their families for blood donations and for their participation in the CORKUM registry. We would like to thank all CORKUM investigators and staff. The authors declare no conflict of interest. Data available upon reasonable request from the authors. Pneumonic plasma upregulated TP1 ) IFIT3 IFIT1 IRF5P1 IFITM3P5 IFI44L IFI27 IRF4 IFI44 IFITM3P7 IFI6 IFIT1P1 MX1 IFI30 IFITM3 ISG15 SIGLEC1 IFITM9P IFIT2 IFI35 IRF7 IFITM8P XAF1 RSAD2 MX2 IFI27L1 IRF8 LY6E IRF9 IRF6 IRF2 IFIT6P IFIH1 IFITM5 ISG20 MT2A IFIT5 IRF1-AS1 IFITM1 IRF3 IFITM3P9 IRF2BP1 IFITM2 IFI16 IFI27L2 IRF2BPL IFITM10 IFITM3P6 IRF1 IRF2BP2 IRF5 IFITM3P1 ISG20L2 IFITM4P IFITM3P4 IFITM3P3 0 2 4 Log(FC) IFITM10 IRF6 IFIT1 IRF4 IFITM3P3 IFI27 IFIT3 IFI44 IFI44L IFI6 RSAD2 ISG15 IRF5 IFIT2 MX1 IFITM3 MX2 XAF1 ISG20 IFIT5 IFITM9P IRF7 SIGLEC1 LY6E IFI30 IFITM1 IFI35 ISG20L2 IRF2BP1 IFITM5 IFITM3P2 IRF9 IFIH1 IFI16 IFIT6P IRF1-AS1 IFITM2 IFI27L2 IRF2 IFIT1B IRF3 IFITM3P1 MT2A IRF1 IRF2BPL IFI27L1 IFITM3P9 IRF2BP2 IRF8 IFITM3P6 IFIT1P1 0 2 4 Log (FC) IFI27 IFIT1 SIGLEC1 IFI44L ISG20 ISG15 IFIT2 IFIT3 RSAD2 IFITM3 IFI6 IFITM9P IFI44 MX1 LY6E XAF1 IFIT5 MX2 IFI27L1 IFIH1 IRF7 IFI35 MT2A IFITM10 IFITM2 IFITM3P2 IFITM1 IRF1-AS1 IFI27L2 IFI16 IRF2 IRF5 IRF2BP1 IRF9 IRF8 IRF3 IRF2BP2 IFI30 ISG20L2 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D4 D60 D60 D60 D60 D60 D60 D60 D60 D60 D60 D60 D60 D60 IFIT3 IFIT1 IRF5P1 IFITM3P5 IFI44L IFI27 IRF4 IFI44 IFITM3P7 IFI6 IFIT1P1 MX1 IFI30 IFITM3 ISG15 SIGLEC1 IFITM9P IFIT2 IFI35 IRF7 IFITM8P XAF1 RSAD2 MX2 IFI27L1 IRF8 LY6E IRF9 IRF6 IRF2 IFIT6P IFIH1 IFITM5 ISG20 MT2A IFIT5 IRF1-AS1 IFITM1 IRF3 IFITM3P9 IRF2BP1 IFITM2 IFI16 IFI27L2 IRF2BPL IFITM10 IFITM3P6 IRF1 IRF2BP2 IRF5 IFITM3P1 ISG20L2 IFITM4P IFITM3P4 IFITM3P3 0 5 IFI27 IFIT1 SIGLEC1 IFI44L ISG20 ISG15 IFIT2 IFIT3 RSAD2 IFITM3 IFI6 IFITM9P IFI44 MX1 LY6E XAF1 IFIT5 MX2 IFI27L1 IFIH1 IRF7 IFI35 MT2A IFITM10 IFITM2 IFITM3P2 IFITM1 IRF1-AS1 IFI27L2 IFI16 IRF2 IRF5 IRF2BP1 IRF9 IRF8 IRF3 IRF2BP2 IFI30 ISG20L2 A novel coronavirus from patients with pneumonia in China A pneumonia outbreak associated with a new coronavirus of probable bat origin Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan Clinical and immunological features of severe and moderate coronavirus disease 2019 A dynamic COVID-19 immune signature includes associations with poor prognosis Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Pathogenesis of COVID-19-induced ARDS: implications for an ageing population COVID-19: consider cytokine storm syndromes and immunosuppression An inflammatory cytokine signature predicts COVID-19 severity and survival Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Dysregulation of type I interferon responses in COVID-19 Lack of IFNgamma signaling attenuates spread of influenza A virus in vivo and leads to reduced pathogenesis Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy A single-cell atlas of the peripheral immune response in patients with severe COVID-19 Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 Vascular neutrophilic inflammation and immunothrombosis distinguish severe COVID-19 from influenza pneumonia A Systematic Review of Asymptomatic Infections with COVID-19 Hospitalization rates and characteristics of patients hospitalized with laboratoryconfirmed coronavirus disease 2019-COVID-NET, 14 States COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention Zhong NS and China Medical Treatment Expert Group for C. Clinical Characteristics of Coronavirus Disease 2019 in China Plasma proteomics identify biomarkers and pathogenesis of COVID-19 Interferon-Induced Protein 44 and Interferon-Induced Protein 44-Like Restrict Replication of Respiratory Syncytial Virus IFITM1 plays an essential role in the antiproliferative action of interferon-γ Interferon-Inducible Protein Mx1 Inhibits Influenza Virus by Interfering with Functional Viral Ribonucleoprotein Complex Assembly Regulation of XAF1 expression in human colon cancer cell by interferon beta: activation by the transcription regulator STAT1. Cancer letters ISG15 in antiviral immunity and beyond Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant Functional significance of the perforin/granzyme cell death pathway Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19 Natural killer cell immunotypes related to COVID-19 disease severity The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation The role of galectins in virus infection -A systemic literature review Proinflammatory Proteins S100A8/S100A9 Activate NK Cells via Interaction with RAGE Contribution of CR3, CD11b/CD18 to cytolysis by human NK cells Tetraspanin CD9: A Key Regulator of Cell Adhesion in the Immune System The cancer-natural killer cell immunity cycle CD8 single-cell gene coexpression reveals three different effector types present at distinct phases of the immune response Clinical features of patients infected with 2019 novel coronavirus in Wuhan Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy Granulysin delivered by cytotoxic cells damages endoplasmic reticulum and activates caspase-7 in target cells Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19 Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers α-defensin production Neutrophil-derived alpha defensins control inflammation by inhibiting macrophage mRNA translation Granzyme A induces caspase-independent mitochondrial damage, a required first step for apoptosis Molecular and cellular insights into T cell exhaustion CXCR3 in T cell function 11-color, 13-parameter flow cytometry: identification of human naive T cells by phenotype, function, and T-cell receptor diversity Human T Cell Development, Localization, and Function throughout JunB regulates homeostasis and suppressive functions of effector regulatory T cells AP-1 function and regulation. Current opinion in cell biology T-cell subsets: transcriptional control in the Th1/Th2 decision GATA3 and the T-cell lineage: essential functions before and after T-helper-2-cell differentiation Th1 and Th2 responses: what are they? JUNB/AP-1 controls IFN-gamma during inflammatory liver disease CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells Severe COVID-19 is marked by a dysregulated myeloid cell compartment Nonclassical Monocytes in Health and Disease CD83-stimulated monocytes suppress T-cell immune responses through production of prostaglandin E2 Targeting TMEM176B enhances antitumor immunity and augments the efficacy of immune checkpoint blockers by unleashing inflammasome activation EGFR regulates macrophage activation and function in bacterial infection Amphiregulin enhances regulatory T cellsuppressive function via the epidermal growth factor receptor Epidermal growth factor receptor expression licenses type-2 helper T cells to function in a T cell receptor-independent fashion Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression, and reduced survival in systemic sclerosis Schwettmann L and the KoCo19 collaboration g. Protocol of a population-based prospective COVID-19 cohort study Munich, Germany (KoCo19) Special Issue "IFN-Independent ISG Expression and its Role in Antiviral Cell-Intrinsic Innate Immunity The type I interferon response in COVID-19: implications for treatment Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study. The Lancet T cell responses in patients with COVID-19 Type I and Type III Interferons-Induction, Signaling, Evasion, and Application to Combat COVID-19. Cell host & microbe Early local immune defences in the respiratory tract Interferon-independent upregulation of interferon-stimulated genes during human cytomegalovirus infection is dependent on IRF3 expression Transcriptional regulation of antiviral interferon-stimulated genes Distinct antiviral signatures revealed by the magnitude and round of influenza virus replication in vivo Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine Repurposed antiviral drugs for COVID-19 -interim WHO SOLIDARITY trial results Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients Side effects of interferon-α therapy. Pharmacy world and science Integrating single-cell transcriptomic data across different conditions, technologies, and species Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression PanglaoDB: a web server for exploration of mouse and human single-cell RNA sequencing data Gene ontology: tool for the unification of biology clusterProfiler: an R package for comparing biological themes among gene clusters A Quality Control Tool for High Throughput Sequence Data Platelets in angiogenesis The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads STAR: ultrafast universal RNA-seq aligner Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 Using self-organizing maps for visualization and interpretation of cytometry data Ultrasensitive proteome analysis using paramagnetic bead technology. Molecular systems biology Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues limma powers differential expression analyses for RNA-sequencing and microarray studies STRING 8-a global view on proteins and their functional interactions in 630 organisms Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles